Preventive effect of platelet-activating factor antagonist, Y-24180, against cyclosporine-induced acute nephrotoxicity

Life Sciences

Volumn 68, Issue 10, 2001, Pages 1181-1190

  Kawaguchi, Atsuhiro ^a   Sugimoto, Koh Ichi ^a   Fujimura, Akio ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Acute nephrotoxicity; Cyclosporine A; PAF antagonist; Y 24180

Indexed keywords

4 AMINOHIPPURIC ACID; CYCLOSPORIN; ENDOTHELIN 1; INULIN; ISRAPAFANT; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOXANE B2;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; KIDNEY BLOOD FLOW; KIDNEY VASCULAR RESISTANCE; MALE; NEPHROTOXICITY; NONHUMAN; RAT; VASOCONSTRICTION;

ANIMALS; AZEPINES; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; HEMODYNAMIC PROCESSES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MALE; PLATELET ACTIVATING FACTOR; RATS; RATS, WISTAR; THROMBOXANE B2; TRIAZOLES;

RATTUS NORVEGICUS;

EID: 0035951389     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(00)01028-6     Document Type: Article

References (31)

1. Therapeutic strategies in the prevention of acute renal failure
2. Platelet-activating factor: A mediator for clinicians
3. Potential role of platelet activating factor in acute renal failure
4. Actions of cyclosporin A on cultured rat mesangial cells
5. Sequential agonist activation and site-specific mediation of acute cyclosporine constriction in rat renal arterioles
6. Preventive effects of two PAF-antagonists, PMS 536 and PMS 549, on cyclosporin-induced LLC-PK1 oxidative injury
7. Effect of platelet-activating factor antagonist on cyclosporine nephrotoxicity. Glomerular hemodynamics evaluation
8. Prevention of cyclosporin nephrotoxicity with a platelet-activating factor (PAF) antagonist
9. Suppressive effects of Y-24180, a long-acting antagonist for platelet-activating factor, on allergic pulmonary eosinophilia in mice
10. Inhibition of activation of human peripheral blood eosinophils by Y-24180, an antagonist to platelet-activating factor receptor
11. Evaluation of methods for the analysis of low insulin concentrations in serum
12. The renal clearances of substituted hippuric acid derivates and other aromatic acids in dog and man
13. Detection of immunoreactive endothelin in plasma of hemodialysis patients
14. 2 levels in rats subjected to pancreas transplantation
15. Inhibition of eosinophil activation in bronchoalveolar lavage fluid from atopic asthmatics by Y-24180, an antagonist to platelet-activating factor
16. Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma
17. Suppressive effects of Y-24180, a receptor antagonist to platelet activating factor (PAF), on antigen-induced asthmatic responses in guinea pigs
18. Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity
19. Stimulatory effect of cyclosporine A on endothelin secretion by a cultured renal epithelial cell line, LLC-PK1 cells
20. FK 506 mechanism of nephrotoxicity: Stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro
21. Role of endothelin in renal function and dysfunction
22. Effects of BQ-123 on renal function and acute cyclosporine-induced renal dysfunction
23. Prevention of cyclosporine A-induced renal vasoconstriction by the endothelin receptor antagonist SB 209670
24. Renal effects and mesangial cell contraction induced by endothelin are mediated by PAF
25. A role for platelet-activating factor in endothelin-1-induced rat mesangial cell proliferation
26. 2 receptor antagonists on cyclosporin A renal vasoconstriction
27. 4 in mediating cyclosporine-induced acute renal failure
28. A role for leukotrienes in cyclosporine nephrotoxicity
29. 2 production in cultured rat mesangial cells by platelet activating factor: Inhibition by a specific receptor antagonist
30. Thromboxane mediates the renal hemodynamic effects of platelet activating factor
31. Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A